Citations

Clear

89 citation(s) found for "Lightner, A L".

Volvulus of the ileal pouch–anal anastomosis: a meta-narrative systematic review of frequency, diagnosis, and treatment outcomes
Jawoosh, Muhammad , Haffar, Samir , Deepak, Parakkal , Meyer, Alyssa J. , Raffals, Laura H., Murad, M. Hassan , Buttar, Navtej , Bazerbachi, Fateh , Meyers, Alyssa, Bazerbachi, F , Murad, M Hassan , Deepak, Parakkal , Lightner, Amy L. , Larson, David W.

Mayo Clinic

Gastroenterology Report | August 15, 2019 | Volume: 7 | Issue: 6 | Pages: 403-410

10.1093/gastro/goz045 | PMID 31857902 Get It

Abstract Background Proctocolectomy with ileal pouch–anal anastomosis (IPAA) is the surgical procedure of choice for medically refractory ulcerative colitis and familial adenomatous polyposis. While rare, a pouch volvulus can occur. We aimed to determine the frequency, presentation, and management approach of pouch volvulus in patients with IPAA. Methods A systematic search of published literature was performed by a medical reference librarian on 10 August 2018 and two independent reviewers identified relevant publications, extracted data, and assessed the methodological quality based on a validated tool. A retrospective review of the Mayo Clinic electronic medical records identified one case of pouch volvulus between January 2008 and August 2018. Results The frequency of pouch volvulus from one large published study reporting long-term outcomes of IPAA was 0.18% (3/1,700). A total of 22 patients (18 ulcerative colitis) were included (median age 32 years, 73% females). Median time to volvulus after IPAA was 36 months while median interval to volvulus diagnosis from symptom onset was 24 hours. Abdominal pain was the most commonly reported symptom (76%). The diagnosis was made primarily by abdominal computed tomography (13/17 patients, 76%). Endoscopic treatment was successful in 1 of 11 patients (9%). Surgery was performed in 20 patients and pouch-pexy and pouch excision were the most frequent surgical operations. A redo IPAA was performed in five patients (25%). Conclusion Pouch volvulus is a rare but serious complication of IPAA and should be suspected even in the absence of obstruction symptoms. Endoscopic treatment often fails and surgery is effective when performed early.
P098 Anti-TNF biologic therapy does not increase postoperative morbidity in pediatric Crohn's patients
Alsughayer, Ahmad, Nicholas, M Hernandez, Edward, Loftus, Laura, Raffals, Faubion, William, Amy, Lightner

Mayo Clinic

American Journal of Gastroenterology | July 21, 2019 | Volume: 114 | Issue: 1 | Pages: S26-S26

10.14309/01.ajg.0000578464.92346.ab Get It

BACKGROUND: Limited knowledge exists as to what impact preoperative biologic therapy has on post-operative complications in pediatric patients undergoing abdominal surgery for Crohn's disease (CD). Therefore, we sought to determine the 30-day postoperative infectious complication rate among pediatric CD patients who received biologic therapy within 12 weeks of an abdominal operation. METHODS: A retrospective chart review was performed on pediatric (<18 years of age) CD patients who underwent an abdominal operation between 1/1/2008 and 12/31/2017. Patients were grouped according to whether they received an anti-TNF (infliximab, adalimumab, certolizumab pegol) or no biologic therapy within 12 weeks prior to the operation. The primary outcome was a the overall 30-day postoperative infectious complication rate. Secondary outcomes included 30-day readmission rate and return to the operating room (ROR). RESULTS: A total of 69 pediatric CD patients met inclusion criteria (n = 54 anti-TNF therapy, n = 15 received no biologic therapy). There were no differences between the anti-TNF and no biologic cohorts with respect to demographics or CD characteristics. No significant differences in overall 30-day postoperative infectious complications existed between patients exposed to anti-TNF agents and those with no preoperative exposure, or in its subcategories of surgical infectious complications and non-surgical infectious complications. There was also no difference in the rate of ileus, readmission, or ROR. CONCLUSION(S): Preoperative exposure to anti-TNF biologic therapy does not add to overall or infectious 30-day postoperative morbidity in pediatric CD patients.
Report From Advances in Inflammatory Bowel Diseases 2018: An Update
Ashburn, Jean, Fleshner, Phillip , Kotze, Paulo Gustavo , Remzi, Feza H. , Strong, Scott A. , Kotze, Paulo G , Lightner, Amy L.

Mayo Clinic

Diseases of the Colon & Rectum | May 16, 2019 | Volume: 62 | Issue: 6 | Pages: 659-660

10.1097/dcr.0000000000001402 | PMID 31094957 Get It

Cell-based Therapy for Perianal Fistulising Crohn’s Disease
Kotze, Paulo Gustavo , Spinelli, Antonino , Lightner, Amy Lee, Kotze, Paulo G , Spinelli, Antonino , Lightner, Amy L.

Mayo Clinic

Current Pharmaceutical Design | May 14, 2019 | Volume: 25 | Issue: 1 | Pages: 41-46

10.2174/1381612825666190308095651 | PMID 31092172 Get It

Background: The management of complex perianal fistulas in Crohn’s disease (CD) represents a challenge for patients, gastroenterologists and colorectal surgeons. There are clear limitations with current medical and surgical options, and healing rates remain far from what is expected. A multidisciplinary approach with optimized medical therapy, usually anti-TNF agents, associated with setons and additional surgical techniques is currently the best strategy to aim fistula healing. Methods: A comprehensive review of the literature was conducted on the use of mesenchymal stem cells (MSCs). Results: The use of mesenchymal stem cells (MSCs) has recently emerged as a promising new therapeutic strategy for complex fistulas in CD patients. This review summarizes the evidence of the use of MSCs in complex CD fistulas, by exploring in detail the types of cells that can be used and their modes of delivery. Additionally, the results of the most recent phase III randomized trial with local MSCs injection are described, and future challenges of this therapeutic option are discussed. Conclusion: The use of MSCs represents hope for better outcomes in patients with CD-related perianal fistulas. More research in the field will help to position this specific therapy in treatment algorithms.
Idiopathic myointimal hyperplasia is a distinct cause of chronic colon ischaemia
Anderson, Bradley J. , Smyrk, Thomas C. , Graham, Rondell P. , Sweetser, Seth , Graham, Rondell P , Anderson, B., Lightner, Amy L.

Mayo Clinic

Colorectal Disease | May 10, 2019 | Volume: 21 | Issue: 9 | Pages: 1073-1078

10.1111/codi.14685 | PMID 31074117 Get It

AbstractAimColon ischaemia (CI) is most commonly an acute and reversible manifestation of a transient, non‐occlusive decrease of blood flow in the colonic microvasculature. Irreversible complications are uncommon and the progression to chronic CI remains controversial. Our objective was to identify cases of chronic CI and assess for distinct clinicopathological features.MethodA retrospective review was performed of CI patients having symptom chronicity of ≥ 1 month and ischaemic histology at our institution from 1994 to 2015. Demographic, clinical, endoscopic, radiological, pathological and outcome variables were abstracted. Histological evaluation was performed by two gastrointestinal pathologists.ResultsFifteen patients (n = 9; 67% men) with a median age of 65 years (range 22–88) were identified. The most common presenting symptoms were diarrhoea and abdominal pain (n = 6, 86%; n = 5, 71%, respectively). The typical endoscopic appearance was segmental ulceration of the sigmoid colon (n = 6, 75%). Vascular imaging showed patent mesenteric vessels in all patients. Histopathological evaluation revealed venous intimal hyperplasia consistent with idiopathic myointimal hyperplasia of the mesenteric veins (IMHMV) in eight patients; the remainder showed non‐specific ulceration and fibrosis. Surgical resection was performed in seven IMHMV patients, resulting in symptom resolution. On re‐review of pre‐resection biopsies, all IMHMV patients had characteristic changes of hyperplastic, thick‐walled, hyalinized vessels in the lamina propria.ConclusionsIMHMV is a unique histopathological entity causing chronic CI. The small vessel histological changes in IMHMV are distinctive in colonic resections and undetectable by routine vascular imaging. Preoperative diagnosis of IMHMV is possible with endoscopic biopsy and segmental colon resection is curative.
Development of an Objective Model to Define Near-Term Risk of Ileocecal Resection in Patients with Terminal Ileal Crohn Disease
Alsughayer, Ahmad, Petersen, M. , Bruining, David H. , Bartlett, David J. , Mathis, Kellie L. , Petersen, Molly, Grass, Fabian , Fletcher, Joel G. , Lightner, Amy L.

Mayo Clinic

Inflammatory Bowel Diseases | May 3, 2019 | Volume: 25 | Issue: 11 | Pages: 1845-1853

10.1093/ibd/izz079 | PMID 31050733 Get It

Abstract Background The decision to either escalate medical therapy or proceed to ileocecal resection (ICR) in patients with terminal ileal Crohn disease (CD) remains largely subjective. We sought to develop a risk score for predicting ICR at 1 year from computed tomography or magnetic resonance enterography (CTE/MRE). Methods We conducted a retrospective cohort study including all consecutive adult (> 18 years) patients with imaging findings of terminal ileal CD (Montreal classification: B1, inflammatory predominant; B2, stricturing; or B3, penetrating) on CTE/MRE between January 1, 2016, and December 31, 2016. The risk for ICR at 6 months and at 1 year of CTE/MRE and risk factors associated with ICR, including demographics, CD-specific immunosuppressive therapeutics, and disease presentation at the time of imaging, were determined. Results Of 559 patients, 121 (21.6%) underwent ICR during follow-up (1.4 years [IQR 0.21–1.64 years]); the risk for ICR at 6 months and at 1 year was 18.2% (95% CI 14.7%–21.6%) and 20.5% (95% CI 16.8%–24.1%), respectively. Multivariable analysis revealed Montreal classification (B2, hazard ratio [HR] 2.73, and B3, HR 6.80, both P < 0.0001), upstream bowel dilation (HR 3.06, P < 0.0001), and younger age (19–29 years reference, 30–44 years, HR 0.83 [P = 0.40]; 45–59 years, HR 0.58 [P = 0.04], and 60+ years, HR 0.45 [P = 0.01]) to significantly increase the likelihood of ICR. A predictive nomogram for interval ICR was developed based on these significant variables. Conclusions The presence of CD strictures, penetrating complications, and upstream bowel dilation on CTE/MRE, combined with young age, significantly predict ICR. The suggested risk model may facilitate objective therapeutic decision-making.
Vedolizumab in the Perioperative Management of Inflammatory Bowel Disease
Loftus, Edward V. , McKenna, Nicholas P. , Raffals, Laura E. , Loftus, Edward V , McKenna, Nicholas P , Lightner, Amy L.

Mayo Clinic

Current Drug Targets | March 27, 2019 | Volume: 20 | Issue: 13 | Pages: 1317-1322

10.2174/1389450120666190325130142 | PMID 30914021 Get It

Background: : The isolated effect of vedolizumab on increased postoperative complications remains debated, similar to the controversial data on anti-TNF and postoperative complications. Objective: : To determine the risk of vedolizumab on postoperative complications. Method:: A review of the literature available to date on studies comparing postoperative outcomes in vedolizumab-treated versus non-vedolizumab-treated patients was performed. Studies were stratified by those which combined all inflammatory bowel disease together, those specifically focusing on Crohn’s disease or ulcerative colitis individually, and those which included pediatric patients alone. Results:: The data remains controversial in both the adult and pediatric literature regarding the association of vedolizumab and increased postoperative complications. The strongest association between vedolizumab and an increased risk of postoperative infectious complications seems to be in the Crohn’s disease literature. Conclusion:: Vedolizumab may be associated with an increased risk of postoperative infectious complications in Crohn’s disease, but the literature remains controversial due to difficulty in isolating the effect of the biologic alone in a chronically ill, heterogeneous patient population who are on multiple medications including corticosteroids.
Congress Report from the 13th Annual Scientific Meeting of the European Society of Coloproctology
Brady, R , Spinelli, Antonino , Spinelli, Antonino , Lightner, Amy L.

Mayo Clinic

Diseases of the Colon & Rectum | March 7, 2019 | Volume: 62 | Issue: 4 | Pages: 399-402

10.1097/dcr.0000000000001346 | PMID 30844968 Get It

Editorial Commentary
Lightner, Deborah J.

Mayo Clinic

Urology Practice | February 22, 2019 | Volume: 6 | Issue: 2 | Pages: 105-105

10.1097/01.upj.0000554253.80734.77 | PMID 37300093 Get It

Does Metabolic Syndrome Increase the Risk of Postoperative Complications in Patients Undergoing Colorectal Cancer Surgery?
Shariq, Omair A. , Hanson, Kristine T. , McKenna, Nicholas P. , Dozois, Eric J. , Mathis, Kellie L. , Habermann, Elizabeth B. , Kelley, Scott R. , Habermann, Elizabeth , McKenna, Nicholas P , Lightner, Amy L. , Hanson, Kristine

Mayo Clinic

Diseases of the Colon & Rectum | February 2, 2019 | Volume: 62 | Issue: 7 | Pages: 849-858

10.1097/dcr.0000000000001334 | PMID 31188186 Get It

BACKGROUND: Metabolic syndrome is associated with poorer postoperative outcomes after various abdominal operations. However, the impact of metabolic syndrome on outcomes after colorectal cancer surgery remains poorly described. OBJECTIVE: The purpose of this study was to determine the association between metabolic syndrome and short-term postoperative outcomes in patients undergoing elective colorectal cancer surgery. DESIGN: This was a retrospective cohort study. SETTINGS: This study used a national multicenter database. PATIENTS: Adult patients who underwent elective colectomy for colorectal cancer from 2010 to 2016 were identified in the American College of Surgeons National Surgical Quality Improvement Program database. MAIN OUTCOME MEASURES: Thirty-day postoperative mortality and morbidity, unplanned reoperation, unplanned readmission, operative time, and length of stay were measured. RESULTS: A total of 91,566 patients were analyzed; 7603 (8.3%) had metabolic syndrome. On unadjusted analysis, metabolic syndrome was associated with an increased risk of 30-day overall morbidity, pulmonary complications, renal complications, septic complications, cardiac complications, wound complications, blood transfusion, longer length of stay, and unplanned readmissions. On multivariable analysis, metabolic syndrome remained significantly associated with renal complications (OR = 1.44 (95% CI, 1.29–1.60)), superficial surgical site infection (OR = 1.46 (95% CI, 1.32–1.60)), deep surgical site infection (OR = 1.40 (95% CI, 1.15–1.70)), wound dehiscence (OR = 1.47 (95% CI, 1.20–1.80)), and unplanned readmissions (HR = 1.24 (95% CI, 1.15–1.34)). The risks of overall morbidity, cardiac and septic complications, and prolonged length of stay for laparoscopic procedures were significantly associated with diabetes mellitus rather than metabolic syndrome as a composite entity. LIMITATIONS: This study was limited by its retrospective design and inability to analyze outcomes beyond 30 days. CONCLUSIONS: Patients with metabolic syndrome undergoing elective surgery for colorectal cancer have an increased risk of 30-day postoperative renal complications, wound complications, and unplanned hospital readmissions. A multidisciplinary approach involving lifestyle modifications and pharmacologic interventions to improve the components of metabolic syndrome should be implemented preoperatively for these patients. See Video Abstract at http://links.lww.com/DCR/A909.